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Bidirectional Relationship Between Metabolic Syndrome 
and Erectile Dysfunction
Wen-Jing Liu*
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Metabolic syndrome is highly correlated with erectile dysfunction (ED) according to 
direct and indirect evidence. The results of individual studies have shown that the 
frequency of ED in patients with metabolic syndrome varies between 26.7–76.2% 
among ethnic groups. ED occurs earlier and remains longer in patients with meta-
bolic syndrome compared with those with organic ED without metabolic syndrome. 
The prevalence of ED increases and the International Index of Erectile Function 
score decreases as the number of abnormal metabolic items of metabolic syndrome 
increases. The pathogenesis of ED in patients with metabolic syndrome is likely mul-
tifactorial in nature, but endothelial dysfunction is the most important mechanism. 
Lifestyle modifications, including weight control may, be one of the best strategies 
for treating ED patients with metabolic syndrome. When treating an ED patient, 
physicians should determine the status of cardiac risks and metabolic syndrome to 
decrease heart diseases and promote the patient’s health.
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Many studies have shown a correlation between athero-
sclerosis and erectile dysfunction (ED). One study consid-
ered that cardiovascular disease (CVD) may explain the 
etiology of ED in more than 50% of cases of ED.1 In differ-
ent study populations, approximately 5–56% of ED pa-
tients reported CVDs.2–4 Furthermore, a high proportion 
(44–75%) of symptomatic cardiovascular patients have 
ED.5–8 Various risk factors of CVD, such as diabetes, hy-
pertension, dyslipidemia, and smoking, have also been 
shown to have a close relationship with ED. Recently, 
metabolic syndrome (syndrome X, insulin-resistance 
syndrome) was identified as consisting of a constellation 
of metabolic abnormalities that confer increased risks of 
CVD and diabetes mellitus. The relationship of meta-
bolic syndrome with CVD has been a hot topic, and data 
have also indicated a positive correlation between them. 
We address the question of “what is the relationship 
between metabolic syndrome and ED?” in this article.
2.  Definition of Metabolic Syndrome
Metabolic syndrome has also been called the deadly 
quartet, syndrome X, and syndrome X plus. This implies 
that a person simultaneously has several abnormal met-
abolic factors, such as high blood sugar, high blood lipid, 
high blood pressure, a high body mass index (BMI), high 
waist circumference, and insulin resistance. However, 
definitions of metabolic syndrome are different among 
the different international groups. For example, insulin 
resistance is required for the definitions of the World 
Health Organization and European Group for the Study 
of Insulin Resistance, but it is not a required item in the 
definition of the National Cholesterol Education Program 
and Adult Treatment Panel III (NCEP ATP III).9,10 Add-
itionally, the American College of Endocrinology pro-
posed excluding obesity from the definition of metabolic 
syndrome because they thought obesity was a cause of 
insulin resistance, not an outcome. Diabetes has also 
been questioned by some experts because of its high 
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cardiovascular risk compared with pre-diabetes and other 
risk factors.
While the current definitions of metabolic syndrome 
proposed by expert groups slightly differ, the definition 
of the NCEP ATP III seems to be more widely used in the 
literature because it is more helpful for investigators. 
Another definition proposed by the International 
Diabetes Federation (IDF) in 2005 is similar to that of the 
NCEP ATP III, and it has also attracted the attention of 
investigators and has been increasingly used in stud-
ies.11 The exact definitions of metabolic syndrome by 
the NCEP ATP III and IDF are given in Tables 1 and 2.
According to the definition of the NCEP ATP III, a case 
of metabolic syndrome is defined as having at least three 
abnormal items among waist circumference, triglyceride 
levels, high-density lipoprotein (HDL) cholesterol levels, 
blood pressure, and fasting glucose levels. The NCEP ATP 
III is slightly different compared with the IDF definition. 
Waist circumference beyond the cutoff point is required 
for a person to have metabolic syndrome according to the 
IDF definition. If a person has an abnormal waist circum-
ference (central obesity) plus any other two abnormal 
items that person is regarded as having metabolic syn-
drome. In Taiwan, the Bureau of Health Promotion also 
proposed a local definition of metabolic syndrome for 
Taiwanese. The revised version released in 2006 is simi-
lar to the modified NCEP definition but waist circumfer-
ence cutoff points were changed to ≥ 90 cm for men 
and ≥ 80 cm for women.
3.  The Relationship Between Metabolic
Syndrome and ED
All of the components of metabolic syndrome are common 
risk factors for CVD. Therefore, it is reasonable to pro-
pose that metabolic syndrome may be related to ED, 
and this suggests that endothelial dysfunction is an im-
portant mechanism responsible for metabolic syndrome 
causing ED.
There are some data showing risk factors related to 
ED. Diabetic patients have more frequent and more se-
vere ED compared with patients with other cardiovascu-
lar risk factors. The quality of life of diabetic ED patients 
is lower than that of non-diabetic ED patients.12 Walczak 
et al. found that self-reported ED patients had a high 
prevalence of obesity.13 Another study by Bacon et al. 
showed that people with a BMI of > 28.7 have a 30% 
greater risk of experiencing ED compared with those 
with a BMI of < 25.14 With regard to hyperlipidemia, Wei 
et al. showed that the relative risk of ED for male patients 
with a total cholesterol > 240 mg/dL was 1.83 compared 
with those with a total cholesterol < 180 mg/dL.15 Con-
versely, the relative risk of ED for patients with a HDL 
Table 1 NCEP definition of metabolic syndrome10
Risk factor Value of the cutoff point
Abdominal obesity
(waist circumference)
 Men ≥ 102 cm
 Women ≥ 88 cm
Triglyceride level  ≥ 150 mg/dL or under specific
 treatment for this lipid abnormality
HDL
 Men < 40 mg/dL or under specific
 treatment for this lipid abnormality
 Women < 50 mg/dL or under specific
 treatment for this lipid abnormality
Blood pressure ≥ 130/ ≥ 85 mmHg or under
 specific treatment for hypertension
Fasting glucosea ≥ 100 mg/dL or diabetic patient
 under treatment.
Metabolic syndrome is defined as having at least three abnormal 
items among waist circumference, triglyceride level, HDL 
cholesterol, blood pressure, and fasting glucose. aFasting glucose 
when initially proposed in 2001 was defined as ≥ 110 mg/dL. 
NCEP = National Cholesterol Education Program; HDL = high-density 
lipoprotein cholesterol.
Table 2  Metabolic syndrome for the Taiwanese11 by the new International Diabetes Federation (IDF) definition
According to the new IDF definition, for a person to be defined as having metabolic syndrome they must have:
Central obesity (defined as a waist circumference of ≥ 90 cm for Taiwanese men and ≥ 80 cm for Taiwanese women, with 
ethnicity specific values for other groups) plus any two of the following four factors:
1. Raised triglyceride levels: ≥ 150 mg/dL (1.7 mmol/L), or having specific treatment for this lipid abnormality
2.  Reduced high-density lipoprotein cholesterol: < 40 mg/dL (1.03 mmol/L*) in males and < 50 mg/dL (1.29 mmol/L*) in females, 
or having specific treatment for this lipid abnormality
3. Raised BP: systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg, or treatment of previously diagnosed hypertension
4.  Raised FPG ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes. If > 5.6 mmol/L or 100 mg/dL, OGTT is 
strongly recommended but it is not necessary to define the presence of the syndrome
*These values were updated from those originally presented to ensure consistency with the ATP III cutoff points. BP = blood pressure; 
FPG = fasting plasma glucose; OGTT = oral glucose tolerance test.
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cholesterol of > 60 mg/dL was 0.3 compared with patients 
with a HDL cholesterol of < 30 mg/dL.15
Some cross-sectional studies have correlated meta-
bolic syndrome with ED, but few prospective studies 
have investigated this issue. Grover et al. found that the 
odds ratio (OR) of having ED with metabolic syndrome 
was 1.45, and metabolic syndrome was an independent 
risk factor predicting ED.16 Gunduz et al. concluded that 
metabolic syndrome has a high correlation with ED.17 
Demir showed that the International Index of Erectile 
Function (IIEF) score in patients with metabolic syndrome 
was significantly lower than those without metabolic 
syndrome, and the IIEF score decreased as the number 
of abnormal metabolic items increased.18 Therefore, they 
suggested that metabolic syndrome is a risk factor for ED. 
Esposito and colleagues noted a strong correlation be-
tween the prevalence of ED and the number of abnormal 
metabolic items.19
4.  Physical Activity, Alcohol Consumption, 
and ED
Physical activity has been shown to have protective ef-
fects against CVD via the mechanism of improving glucose 
tolerance, lowering blood pressure, preventing obesity, 
and improving the lipid profile and endothelial function.20 
Daily low-dose alcohol has also been shown to confer CVD 
protection by improving the HDL level, insulin sensitivity, 
and postprandial glucose level.21 Therefore, study results 
exploring the relationships of physical activity and alcohol 
consumption with ED can also be used as evidence for the 
correlation between metabolic syndrome and ED.
4.1.  Physical activity and ED
Results from the Health Professionals Follow-up Study 
showed that weekly physical activity of 2.7–7.6, 7.7–16.5, 
16.6–32.6, and > 32.6 metabolic equivalents (METs) sig-
nificantly decreased the risk of ED by 10%, 10%, 20%, 
and 30%, respectively, compared with physical activity 
of < 2.7 METs per week. The authors suggested that 
physical activity was significantly inversely associated 
with erectile function.22 Prospective results from the 
Massachusetts Male Aging Study revealed that a daily 
energy consumption of > 200 kcal may decrease the risk 
of ED by 29%, but this was not statistically significiant.23 
A meta-analysis study from Hong Kong summarized a 
cross-sectional study, two cohort studies, and one ran-
domized clinical trial, and the results showed summary 
estimates for adjusted ORs of physical activity on ED of 
0.53 (0.31–0.91), an OR of 0.63 (0.43–0.93) for moder-
ate physical activity, and an OR of 0.42 (0.22–0.82) for 
high physical activity. The authors suggested that an 
apparent “protective” effect of physical activity on ED 
should be further investigated using large-scale cohort 
studies or randomized clinical trials.24
4.2.  Alcohol consumption and ED
Results from both the Health Professionals Follow-up 
Study and Massachusetts Male Aging Study found that 
the effect of alcohol on ED was neutral.22,23 Another 
Finnish 5-year follow-up study also reached the same 
conclusion.25 A meta-analysis reviewed the results of 
one cross-sectional study and two cohort studies.26 The 
authors noted that there was a protective association of 
alcohol against ED in the cross-sectional study, but the 
two cohort studies demonstrated no significant findings. 
Therefore, they suggested that further research was re-
quired to confirm the effect of alcohol on ED develop-
ment. Findings of a recently published study from Western 
Australia suggested a modest negative association be-
tween alcohol consumption and ED, and CVD and ciga-
rette smoking confounded the association. On further 
adjustment for CVD and cigarette smoking, age-adjusted 
odds of ED were reduced by 25–30% among alcohol 
drinkers.27
5.  Testosterone in Metabolic Syndrome 
and ED
The scientific evidence from cross-sectional and cohort 
studies supports an association between low testosterone/
low sex hormone binding globulin levels and metabolic 
syndrome.28 Some studies confirmed that testosterone 
treatment reduces waist circumference, a component of 
metabolic syndrome.29,30 Another study administering 
testosterone to restore levels to mid-normal values for a 
duration of 8–9 months found decreased visceral fat 
mass, fasting glucose, lipid levels, and diastolic blood 
pressure, and improved insulin sensitivity.31 All of the 
above evidence confirms the relationship between low 
testosterone and metabolic syndrome.
It is well known that hypogonadism in men usually 
results in loss of libido and potency, which can be restored 
by androgen administration, and testosterone affects 
libido and also exerts essential effects on the anatomical 
and physiological substrates of penile erection.28 There-
fore, in addition to influencing libido and penile erection, 
metabolic syndrome may be another route through which 
hypogonadism affects ED.
6.  Summary of the Current Status of 
Metabolic Syndrome and ED
6.1.  Epidemiology
Metabolic syndrome is highly correlated with ED accord-
ing to direct and indirect evidence from the current liter-
ature. The results of individual studies show that the 
frequency of ED at 26.7–76.2% in patients with metabolic 
syndrome varies among ethnic groups.17–19 ED occurs 
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earlier and remains longer in ED patients with metabolic 
syndrome compared with those with organic ED without 
metabolic syndrome.32 The prevalence of ED increases 
and the IIEF scores decrease as the number of abnormal 
metabolic items of metabolic syndrome increases.18,33 
Age may influence the relationship between metabolic 
syndrome and ED. A study using the IDF definition found 
that metabolic syndrome in men older than 50 years 
was significantly associated with a higher proportion 
of moderate to severe ED, but not in men younger than 
50 years.34
6.2.  Mechanism
6.2.1.  The role of endothelial dysfunction
Endothelial dysfunction is suggested to be a mechanism 
through which metabolic syndrome causes ED. Esposito 
et al. found that the prevalence of ED and the number of 
abnormal metabolic items are strongly correlated, and 
they also showed that the index of endothelial dysfunc-
tion decreased by 6-fold and C reactive protein in-
creased by more than 3-fold in patients with metabolic 
syndrome.19 A review paper published in 2007 also found 
inflammatory status related to endothelial dysfunction.35 
After performing a comprehensive evaluation of the 
available published data in full-length papers that were 
identified in MedLine up to July 2007, the authors found 
associations among metabolic syndrome, ED, and an 
increased inflammatory state. They also suggested that in-
creased circulating levels of inflammatory and endothelial-
prothrombotic compounds are related to the presence 
and severity of ED. An age-matched case-control study 
showed that penile arterial 5-, 10-, and 20-min peak flow 
velocities in ED patients with metabolic syndrome were 
decreased compared with those of ED patients without 
metabolic syndrome.36 The authors concluded that met-
abolic syndrome appears to be a potential risk factor for 
ED which may exert its effect by decreased arterial inflow 
due to endothelial dysfunction.
6.2.2.  Other proposed pathogenic routes
Endothelial dysfunction is not the only mechanism pro-
posed for how metabolic syndrome affects ED. According 
to data from organic ED patients after a full evaluation, 
including laboratory and ultrasound assessments of en-
dothelial function, Mazo et al. concluded that the patho-
genesis of ED in patients with metabolic syndrome is 
multi-factorial in nature.37 They suggested that ED is pri-
marily caused by arteriogenic disorders which are cou-
pled with neuropathic disorders in almost half the 
patients and with hormonal factors in 1 of 3 patients. 
Apart from the above factors, they also considered 
that the psycho-emotional status is very important in 
the development of ED in patients with metabolic 
syndrome.
7.  Benefits of Lifestyle Modification in 
Treating ED Patients with Metabolic 
Syndrome
A previous study on obese treatment revealed that body 
weight reduction can significantly increase IIEF scores 
and significantly improve the lipid profile, blood pres-
sure, blood sugar, blood insulin, C-reactive protein, and 
interleukin levels.38 That study suggested that lifestyle 
modifications including weight control may be one of 
the best treatments for ED patients with metabolic 
syndrome.
Metabolic syndrome may affect the response to silde-
nafil treatment. A Japanese study using the IDF definition 
demonstrated a negative impact of metabolic syndrome 
on the responsiveness to sildenafil.39 They found that 
erectile function and the response rate to sildenafil de-
creased as the number of metabolic syndrome compo-
nents increased. This implied that when treating ED 
patients with metabolic syndrome, in addition to prescrib-
ing phosphodiesterase type 5 inhibitors, the importance 
of lifestyle modifications should be recognized.
8.  Future Suggestions for Defining 
Metabolic Syndrome
One study found that the NCEP definition of metabolic 
syndrome was better than the IDF definition in predict-
ing hypogonadism and impaired penile blood flow.40 A 
joint interim statement for harmonizing recommenda-
tions for metabolic syndrome was published in October 
2009.41 This article represents the outcome of a meeting 
between several major organizations in an attempt to 
unify criteria. It was agreed that there should not be an 
obligatory component (e.g., the NCEP definition). A sin-
gle set of cutoff points should be used for all compo-
nents except for waist circumference for which further 
work was required. In the interim, national or regional 
cutoff points for waist circumference should be used 
(e.g., the IDF definition). Additionally, Taiwanese can use 
the NCEP definition while the waist circumference cutoff 
points should be changed to ≥ 90 cm for men and ≥ 80 cm 
for women, similar to the 2006 revised form proposed 
by the Taiwan Bureau of Health Promotion.
9.  Conclusions
There is a lot of evidence in the literature suggesting 
a relationship between metabolic syndrome and ED. 
Therefore, sexual health may be a portal to men’s health. 
When treating an ED patient, physicians should use a 
more comprehensive approach to explore the status of 
cardiac risks and metabolic syndrome to decrease heart 
disease and promote the patient’s health.
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